External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.

"Disclosure Daniel Röshammar is a current employee of AstraZeneca. However, this work was not funded by AstraZeneca."

"Swedish Research Council (K2008-58P-20930-04-1, project 2007-7092), the Sahlgrenska Academy at University of Gothenburg (ALFGBG-11067), Göteborg Medical Society, the Research Foundation Swedish Physicians against AIDS, Västra Götalandsregionens FoU-anslag (VGFOUREG-25921). The Mahidol University-Oxford Tropical Medicine Research Unit is supported by the Wellcome Trust of Great Britain. The French Agency on AIDS (ANRS), sponsor, and Pr Cécile Goujard (principal investigator), Dr Anne Marie Taburet (responsible for pharmacology) and Pr France Mentré (responsible for methodology) for giving us access to some of the data of the ANRS 134-COPHAR 3 trial. Thanks to Linda Skeie for her assistance in providing data from the Norwegian patients. DisclosureDaniel Röshammar is a current employee of AstraZeneca. However, this work was not funded by AstraZeneca."